Epineuron announces enrollment of its first patient in REGAIN™

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Epineuron, a clinical-stage nerve care company, recently announced that it has successfully enrolled the first patient in the company’s pivotal trial, REGAIN™. This is a huge milestone for Epineuron and a step towards advancing better care for the treatment of injured peripheral nerves.

Epineuron is an alumnus of OBIO’s BDSP™, CAAP® , H2BB™ and WiHI programs.

Arsheen Kaur
Previous

HDAX Therapeutics’ co-founder announced winner of 2023 Gold Leaf Awards for Next Generation Leadership
Next

OBIO’s EAHN™ supports the evaluation of Huron Digital Pathology’s technology solutions for faster and more accurate diagnoses